Osimertinib/osimertinib latest medical insurance price 2024

Osimertinib/Osimertinib, also known as AZD9291, is a new generation of targeted drugs used to treat non-small cell lung cancer (NSCLC). It mainly targets mutations in the epidermal growth factor receptor (EGFR), especially the EGFR T790M mutation, which is one of the common mechanisms that cause tumors to become resistant to first- and second-generation EGFR inhibitors.

Osimertinib/The original drug Osimertinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The domestic price is about three to four thousand yuan. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The cheaper ones abroad are generic drugs, mainly those sold in Laos and Bangladesh. The price is basically around a few hundred yuan, which is much lower than the domestic price. The ingredients of generic drugs are basically the same as those of the original drugs.

Compared with traditional EGFR inhibitors, osimertinib/osimertinib has higher selectivity and can more effectively inhibit EGFR kinase activity, thereby inhibiting the growth and spread of cancer cells. In addition, Osimertinib/Osimertinib can also penetrate the blood-brain barrier and also has a therapeutic effect on NSCLC patients who have developed brain metastasis.

Osimertinib/Osimertinib's clinical trial results show that it has shown significant efficacy in the treatment of EGFRmutated NSCLC patients. It can not only prolong the progression-free survival of patients, but also improve their quality of life. In addition, Osimertinib is also popular with patients and doctors due to its lower side effects and more convenient dosing regimen.

AlthoughOsimertinibOsimertinib has been highly successful in treating EGFR T790M-mutated NSCLC, but some patients still develop other resistance mechanisms. Therefore, scientists are constantly working hard to find new treatment strategies to further improve the treatment effect and survival rate of NSCLC patients.